ArriVent BioPharma (AVBP) Liabilities and Shareholders Equity (2023 - 2026)
ArriVent BioPharma (AVBP) recorded Liabilities and Shareholders Equity of $394.72 million in Q2 2026, up 46.5% from $269.51 million a year earlier and up 13.0% from the prior quarter.
Powered by 
Analysis
ArriVent BioPharma (AVBP) Liabilities and Shareholders Equity (2023 - 2026) Analysis & Trends
At the end of FY2025, ArriVent BioPharma reported Liabilities and Shareholders Equity of $333.17 million, up 21.2% from FY2024.
- Across earlier years, Liabilities and Shareholders Equity came in at $274.94 million in FY2024 (+68.6%) and $163.1 million in FY2023.
- The Q2 2026 figure is the highest quarterly Liabilities and Shareholders Equity in data going back to Q4 2023.
- On a year-over-year basis, Liabilities and Shareholders Equity has increased for four consecutive quarters, with growth averaging 23.3% over the last seven quarters.
- Per Business Quant, the preceding three quarters came in at $349.3 million (Q1 2026), $333.17 million (Q4 2025) and $326.56 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | ArriVent BioPharma | 1.46 Bn | 1.46 Bn | - | 394.72 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 394.72 Mn |
| Mar 31, 2026 | 349.30 Mn |
| Dec 31, 2025 | 333.17 Mn |
| Sep 30, 2025 | 326.56 Mn |
| Jun 30, 2025 | 269.51 Mn |
| Mar 31, 2025 | 215.50 Mn |
| Dec 31, 2024 | 274.94 Mn |
| Sep 30, 2024 | 292.71 Mn |
| Jun 30, 2024 | 308.86 Mn |
| Mar 31, 2024 | 327.84 Mn |
| Dec 31, 2023 | 163.10 Mn |
API Access
ArriVent BioPharma Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=AVBP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "AVBP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=AVBP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();